P&G Plans Health Care Expansion As Prilosec OTC Sales Continue Falling
This article was originally published in The Tan Sheet
Executive Summary
Double-digit percent volume growth in developing markets helped drive Procter & Gamble's health care sales up 5 percent, but the firm says competition for Prilosec OTC continues to cut into its revenues
You may also be interested in...
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch